Innovative Health Care Models Prove Cost-Effective Amidst Pandemic Pressures

By Staff Writer

September 26, 2023

During the COVID-19 pandemic, hospitals faced immense pressure. Singapore was also grappling with a dengue outbreak, adding to the strain on hospital capacity. This situation led to the rapid implementation of novel care models to treat patients with acute, low-severity medical conditions.

Two of these models, the hospital-at-home (HaH) and ambulatory care team (ACT) models, were used to treat patients with dengue and chest pain respectively. The HaH model allowed patients to receive care at home, while the ACT model provided timely care in a clinic-style setting at the hospital’s emergency department.

An economic evaluation aimed to compare the personnel cost of these models with conventional hospital inpatient care. The results showed that the HaH and ACT models used less personnel time, resulting in reduced costs.

The HaH model for treating dengue was found to be slightly cheaper than conventional care, with estimated savings of 18 SGD per case. The ACT model for treating chest pain showed more significant savings, with an estimated reduction of 126 SGD per case.

These innovative health care models not only alleviate hospital pressure but also potentially reduce hospital-acquired infections, length of stay, and overall health care expenditure. However, a reliable cost analysis of these models remains a priority.

Reference url

Recent Posts

ivonescimab lung cancer treatment
       

Ivonescimab NMPA Approval Signals Breakthrough in Lung Cancer

🚀 🌍 Ivonescimab’s NMPA approval for PD-L1+ NSCLC reshapes oncology!

This chemo-free bispecific antibody outperforms pembrolizumab, boosting PFS/OS in the HARMONi-2 trial. Its dual-action mechanism sets a new standard, driving urgency for market access and policy strategies. Discover why this breakthrough matters for global NSCLC care (and more indications in the pipeline).

Dive into the full article [here] (https://www.akesobio.com/en/media/akeso-news/250426/).

#SyenzaNews #oncology #HealthcareInnovation #PharmaInnovation #NSCLC

CDC hepatitis lab closure
         

Assessing Risks and Opportunities: The Impact of the CDC Hepatitis Lab Closure

🚨 Is the abrupt closure of the CDC’s only hepatitis lab leaving the U.S. vulnerable during an ongoing outbreak?

This article looks into the ramifications of the CDC hepatitis lab closure amid federal layoffs, questioning the impact on outbreak detection and public health. With the lab’s unique capabilities being irreplaceable, what does this mean for our response to hepatitis outbreaks?

Explore the critical insights and implications for our public health infrastructure.

#SyenzaNews #HealthcareInnovation #HealthEconomics #PublicHealth

peanut oral immunotherapy
        

Promising Results for Peanut Oral Immunotherapy

🌟 Ready to change the conversation on peanut allergies?

A recent study from the University of Virginia shines a light on peanut oral immunotherapy (epOIT), revealing that 90% of young children achieved effective desensitization with minimal side effects. This compelling research advocates for early intervention, potentially transforming how we manage this prevalent food allergy.

Dive into the full article to explore how adopting this approach could reshape health policies and enhance quality of life for affected families.

#SyenzaNews #HealthTech #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.